Role of Biological Response Modifiers in the Treatment of Rheumatoid Arthritis-A Review

Authors

  • M Azizul Haque Resident Physician(General), Rajshahi Medical College Hospital, Rajshahi.
  • ARM Saifuddin Ekram Professor of Medicine, Rajshahi Medical College, Rajshahi.
  • Quazi Tarikul Islam Associate Professor of Medicine, Rajshahi Medical College, Rajshahi.

DOI:

https://doi.org/10.3329/taj.v17i1.3494

Keywords:

Rheumatoid arthritis

Abstract

Rheumatoid arthritis is a chronic disease with the potential to cause substantial joint damage and disability. During the past 10 years, improved understanding of the pathophysiology of rheumatoid arthritis has led to several key changes in the approach to therapy. Most important of that is the development of some biological agents interfering with the activity of several important cytokines. Infliximab, etanarcept, and adalimumab are TNF blockers, anakinra is IL-1 receptor antagonist, and rituximab is anti CD-20 monoclonal antibody. These newer agents proved to be useful for alleviating symptoms and slowing the disease progression in the patients with RA who have failed to respond to conventional DMARDs.  

doi: 10.3329/taj.v17i1.3494

TAJ 2004; 17(1) : 71-76

Downloads

Download data is not yet available.
Abstract
121
PDF
65

Downloads

How to Cite

Haque, M. A., Ekram, A. S., & Islam, Q. T. (2009). Role of Biological Response Modifiers in the Treatment of Rheumatoid Arthritis-A Review. TAJ: Journal of Teachers Association, 17(1), 71–76. https://doi.org/10.3329/taj.v17i1.3494

Issue

Vol. 17 No. 1 (2004)

Section

Review Articles